— $2 million in seed funding raised to advance development —
— Kevin Kalish joins EnClear as Vice-President of Research and
Development —
CAMBRIDGE, Mass.–(BUSINESS WIRE)–EnClear
Therapies, a biotechnology company developing device-based therapies
for the treatment of neurodegenerative disease, today announced that the
company had secured approximately $2 million in seed funding and that it
has hired Kevin Kalish as Vice President of Research and Development.
“EnClear is moving forward rapidly in developing our unique approach to
treating Amyotrophic Lateral Sclerosis. Based on our progress to date,
we believe we have a pathway that could see our lead program in human
clinical trials in two years,” said Anthony DePasqua, Chief Executive
Officer and Co-founder, EnClear Therapies. “I’m gratified to have
completed this round of seed financing with partners who believe in our
technology and share our vision of delivering meaningful therapies to
patients living with neurological diseases.”
Partners in the seed financing included Thiel Capital, Bioverge, Sanford
Biosciences and Christian Angermayer‘s Presight Capital.
“EnClear’s approach to ALS has the potential to be the first treatment
option to slow, and potentially even halt, this devastating disease,”
said Rick Gibb, Co-founder and Chief Operating Officer, Bioverge,
Inc. “Bioverge is excited to partner with such an exemplary team and
help support its groundbreaking mission and technology.”
“The addition of Kevin Kalish to our leadership team fills a key role
during this critical phase in the growth of EnClear,” said Mr. DePasqua.
“As the leader of our research and development function, Kevin brings
deep industry and technical knowledge along with the passion to deliver
significant new therapies to improve outcomes for patients.”
“At EnClear we have an amazing opportunity to positively impact
patients’ lives,” said Kevin Kalish. “Our understanding of the
mechanisms and progression of neurological diseases, such as ALS, has
drastically improved over the past several years. EnClear Therapies is
well positioned to take that learning and apply it in novel ways to
extend and enhance the lives of patients living with these devastating
conditions.”
Kevin Kalish Bio
Kevin Kalish has over 15 years’ experience leading R&D, Program
Management and Operations with Medtronic, Boston Scientific and Johnson
and Johnson. Most recently he provided strategic leadership to the
Transformative Solutions business unit at Medtronic. He received his MBA
from Boston College, BSE/MSE from UMass Lowell and is Program Management
Professional certified.
About EnClear Therapies
EnClear Therapies is a Cambridge (USA) based biotechnology company
developing neurology-focused, device-based systems that remove toxic
proteins as therapies for the treatment of neurodegenerative diseases
and provide closed loop delivery & monitoring of cerebrospinal fluids
(CSF). The company’s first products will target improving the lives of
patients with Amyotrophic Lateral Sclerosis (ALS) and Progressive
Supranuclear Palsy (PSP).
https://www.encleartherapies.com.
Contacts
Rob Kloppenburg
Shoreline Biotech Communications
617-930-5595